lung disease

ATS Releases New Primary Ciliary Dyskinesia Diagnostic Guideline

The American Thoracic Society (ATS) has published a new clinical practice guideline to help clinicians diagnose primary ciliary dyskinesia (PCD), the symptoms of which overlap with many other breathing disorders in children, leading to its being undiagnosed or misdiagnosed.

The guideline was published at the ATS website and in the June 15 issue the society’s American Journal of Respiratory and Critical Care Medicine.1


IF YOU LIKE THIS, READ MORE …

New As-Needed Therapy for Mild Asthma Outperforms Maintenance Therapy

ATS: Air Pollution Causes Thousands of Deaths per Year


PCD is a rare, genetically heterogeneous disorder characterized by motile cilia dysfunction. Its clinical manifestations include chronic upper and lower airway disease, laterality defects, and infertility. PCD presents a diagnostic challenge because the condition varies in severity, and its symptoms mimic or overlap with many other pediatric respiratory disorders, including asthma and viral infections.

No consensus-based gold-standard diagnostic test exists for PCD. Transmission electron microscopy (TEM), which has been used for more than 40 years to diagnose PCD by identifying defects of the cilia, is neither highly sensitive or specific for diagnosing PCD.

Accordingly, the ATS expert guideline committee reviewed published evidence evaluating 4 adjuvant methods of diagnosing PCD—genetic testing, nasal nitric oxide (nNO) testing, ciliary beat pattern analysis by digital high-speed video microscopy (HSVM), and immunofluorescence imaging for specific axonemal proteins. They then compared the 4 methods’ diagnostic effectiveness with that of TEM and/or a standard genetic test panel for the presence of PCD mutations.

Each of the 4 methods was evaluated based on its ability to diagnose patients with at least 2 of 4 key features of PCD: year-round daily productive cough; year-round daily nonseasonal rhinosinusitis; neonatal respiratory distress syndrome; and laterality defects such as situs inversus totalis.

In these patients, the guideline committee suggests following:

  • Using an extended genetic test panel (>12 genes) as a diagnostic test over TEM and/or a standard genetic test panel (≤12 genes).
  • Using nNO testing in patients older than 5 years who have tested negative for cystic fibrosis over TEM and/or a standard genetic test panel.
  • Not using ciliary beat frequency analysis by digital HSVM as a replacement diagnostic test for TEM and/or a standard genetic test panel.
  • Not using ciliary beat frequency as a diagnostic test over TEM and/or a standard genetic test panel.

In the absence of a single definitive test for PCD, the guideline recommends that a panel of tests be used to make the diagnosis.

“Unfortunately, no single test can diagnose all cases of PCD, but the most feasible and accurate tests at present are nasal nitric oxide and genetic testing,” said guideline committee co-chair Adam J. Shapiro, MD, in an an assistant professor of pediatrics at McGill University and a pediatric pulmonologist at Montreal Children’s Hospital. “Some patients will need to visit PCD specialty centers to have the proper diagnostic testing performed, and physicians will need to pursue appropriate diagnostic testing on a case-by-case basis, depending upon the available PCD tests and clinical resources in each institution.”2

—Michael Gerchufsky

References:

  1. Shapiro AJ, Davis SD, Polineni D, et al; American Thoracic Society Assembly on Pediatrics. Diagnosis of primary ciliary dyskinesia: an official American Thoracic Society clinical practice guideline. Am J Respir Crit Care Med. 2018;197(12):e24-e39. https://doi.org/10.1164/rccm.201805-0819ST.
  2. New ATS guideline aids in diagnosing primary ciliary dyskinesia [press release]. New York, NY: American Thoracic Society; June 18, 2018. http://www.thoracic.org/about/newsroom/press-releases/journal/new-ats-guideline-aids-in-diagnosing-primary-ciliary-dyskinesia.php. Accessed June 21, 2018.